hBChE-IN-2

CAS No. 2923366-36-1

hBChE-IN-2( —— )

Catalog No. M36924 CAS No. 2923366-36-1

hBChE-IN-2 is a butyrylcholinesterase (BChE) inhibitor and cannabinoid receptor 2 (CB2R) agonist with neuroprotective activity for the study of Alzheimer's disease-like neurological disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 459 In Stock
10MG 657 In Stock
25MG 1026 In Stock
50MG 1386 In Stock
100MG 1832 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    hBChE-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    hBChE-IN-2 is a butyrylcholinesterase (BChE) inhibitor and cannabinoid receptor 2 (CB2R) agonist with neuroprotective activity for the study of Alzheimer's disease-like neurological disorders.
  • Description
    hBChE-IN-2 (compound 15d) is a butyrylcholinesterase (BChE) inhibitor (IC50 of 0.62 μM) and a cannabinoid receptor 2 (CB2R) agonist. hBChE-IN-2 has neuroprotection activities.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    AChR
  • Recptor
    AChR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2923366-36-1
  • Formula Weight
    464.6
  • Molecular Formula
    C27H36N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OC1=CC=C(C=C1)CC2=NC=3C=C(C=CC3N2CCC(C)C)C(=O)N(CC)CC)N(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Philipp Spatz, et al. Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer's Disease Mouse Model. J Med Chem. 2023 May 11;66(9):6414-6435. ?
molnova catalog
related products
  • PNU-282987 free base

    PNU-282987 (free base) is a potent agonist of α7 nicotinic acetylcholine receptor (nAChR) with an EC50 of 154 nM and a functional antagonist of the 5-HT3 receptor with an IC50 of 4541 nM.

  • GSK233705

    GSK233705 (Darotropium bromide) is a muscarinic receptor antagonist used in conjunction with the prevention and treatment of chronic obstructive pulmonary disease (COPD) and asthma in humans.

  • OXOMEMAZINE

    Oxomemazine is a phenothiazine-based histamine H1-receptor blocker with pronounced antimuscarinic activity.